Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31 2023 - 4:30PM
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:
CLLS), a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, announced today that pre-clinical data on MUC1-CAR
T-cells to overcome key challenges of targeting solid tumors, will
be presented at the Society for Immunotherapy of Cancer’s 38th
Annual Meeting (SITC 2023), that will take place on November 1-5,
2023 at San Diego Convention Center in San Diego (CA).
The data will be presented by Laurent Poirot,
Ph.D., SVP Immunology of Cellectis, in a poster session that will
be held November 4th 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San
Diego Convention Center, Hall A.
The poster is number 254 and it is entitled
“TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion
Synergize to Optimize Potency of MUC1-CAR T-cells in Preclinical
Targeting of Triple-Negative Breast Cancer”.
While during SITC 2022 Cellectis presented how
TALEN®-mediated gene editing allows programming of various
functions addressing both safety and potency aspects of allogenic
CAR T-cell therapy, this year the company’s presentation will focus
on the synergistic benefits of ΔPD1-IL12 and TGFBR2-KO attributes
in preclinical models of triple negative breast cancer.
“We demonstrate that combination of the
ΔPD1-IL12 with TGFBR2 KO not only enhanced CAR-T cell activity but
surprisingly limit their accumulation outside the tumor, therefore
reducing the risks of off-tumor toxicity. These cells also show
strong anti-tumor activity against distal tumors when infused
intratumorally”, said Laurent Poirot, Ph.D., SVP Immunology at
Cellectis.
These pre-clinical data highlight the capability
of multi-armored allogeneic CAR T-cells to preserve their activity
despite the immunosuppressive microenvironment, while mitigating
potential safety concerns.
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
23 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“anticipate,” “expect,” “plan,” “could” and “will,” or the negative
of these and similar expressions. These forward-looking statements,
which are based on our management’s current expectations and
assumptions and on information currently available to management,
include statements about the ability to further research and
develop our preclinical candidate products and the potential
benefit of the Company’s preclinical candidate products. These
forward-looking statements are made in light of information
currently available to us and are subject to numerous risks and
uncertainties, including with respect to the numerous risks
associated with biopharmaceutical product candidate development.
With respect to our cash runway, our operating plans, including
product development plans, may change as a result of various
factors, including factors currently unknown to us. Furthermore,
many other important factors, including those described in our
Annual Report on Form 20-F and the financial report (including the
management report) for the year ended December 31, 2022 and
subsequent filings Cellectis makes with the Securities Exchange
Commission from time to time, as well as other known and unknown
risks and uncertainties may adversely affect such forward-looking
statements and cause our actual results, performance or
achievements to be materially different from those expressed or
implied by the forward-looking statements. Except as required by
law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual results
could differ materially from those anticipated in the
forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media contact:
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77
46 93, media@cellectis.com
Investor Relations contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com Ashley R. Robinson, LifeSci
Advisors, +1 617 430 7577
- SITC_2023_abstract released_ENGLISH
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Sep 2023 to Sep 2024